Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liothyronine in Multiple Sclerosis
NCT02760056Phase 1Completed
- Sponsor
- Oregon Health & Science University
- Start
- Jun 2016
- Primary completion
- Jan 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in multiple sclerosis (MS) comparing Liothyronine with Placebo (2 arms). Primary endpoint: Maximum Tolerated Dose at 1 week. Started Jun 2016; status: completed.
02
Drugs
liothyronine
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT02760056.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02760056.